All News
Manifestations of Systemic Sclerosis Sine Scleroderma
Systemic sclerosis (SSc) sine scleroderma is a unique and rare subset of SSc defined by the absence of skin fibrosis. An analysis of the EUSTAR database suggests systemic disease can be a problem, including interstitial lung disease (>40%) and SSc renal crisis (almost 3%).
Read ArticleMono- and Oligo- are Different (8.18.2023)
Dr. Jack Cush reviews the news and journal reports from RheumNow.com this past week.
Read ArticleCOSMOS: Guselkumab's Immunologic Benefits in Psoriatic Arthritis
The IL-23 inhibitor guselkumab was studied in active psoriatic arthritis patients in the phase 3b COSMOS trial, and shown to be clinically effective while reducing multiple effector cytokines, including those associated with the IL-23/IL-17 pathway.
Read ArticleImaging Mass Cytometry to Study Lupus Nephritis
Lupus researchers from the University of Houston are reporting the first use of the powerful imaging mass cytometry to examine the kidneys of patients with systemic lupus erythematosus, as a means of diagnosing lupus nephritis in SLE patients. LN is a severe inflammation of the kidneys and a major cause of death in lupus patients. Up to 60% of SLE patients will develop renal symptoms with 5–20% of those patients progressing to end stage kidney disease within 10 years.
Read ArticleResidual Disease in Controlled Axial Spondyloarthritis
Despite being in a state of remission or low disease activity state, in patients with axial spondyloarthritis, up to 42% may still have residual disease.
Read ArticleStable Safety Outcomes with Abatacept
The safety of abatacept was studied using patients with rheumatoid arthritis (RA) from 7 European registers, revealing safety signals on par with that previously reported with no new safety concerns.
Read ArticleThe Adalimumab Biosimilar Glut
In 2023, three marketed biosimilars (Actemra, Stelara, Humira) had their patents expire, opening opportunities for multiple new biosimilars; but with competition comes a word salad of new drug names, confusion and nonsensical discounts.
Read ArticleGlucocorticoid Affects Weight, but not Blood Pressure in RA
A pooled analysis of 5 randomized controlled trials (RCTs) shows that the effects of 2 years of low-dose glucocorticoid (GC) treatment in rheumatoid arthritis (RA) can significantly increase increase body weight, but not blood pressure.
Read ArticleMonoarticular JIA - a Distinct Clinical Entity
Monoarticular Juvenile Idiopathic Arthritis (monoJIA) is typically classified under oligoarticular JIA, but a recent study suggests it is a separate entity.
Read ArticlePizza and Rheumatoid Arthritis (8.11.2023)
Dr. Jack Cush reviews the news and journal reports from the wonderful wide world of Rheumatology. This week:
Read ArticlePRESTO Tool Predicts the Risk of Psoriatic Arthritis
In research published in Arthritis & Rheumatology, investigators developed and validated a tool called PRESTO that identif
Read ArticleColchicine or Prednisone in CPPD?
The COLCHICORT trial in patients with acute calcium pyrophosphate crystal arthritis (CPPD) demonstrated equivalent efficacy for both colchicine and prednisone, yet different safety signals were seen.
Read ArticlePatient Perspectives on Telemedicine Use During the Pandemic
Research from the COVID-19 Global Rheumatology Alliance included surveys and data gathering from rheumatology patients.
Read ArticleLinks:
Links:
Links:
Links:
Links:
Links:
Links: